Please assess the completion status of the following clinical trial:

Trial Title: ExAblate Conformal Bone System Treatment of Metastatic Bone Tumors for the Palliation of Pain

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Men and women age 18 and older~2. Patients who are able and willing to give consent and able to attend all study visits~3. Patients who are suffering from symptoms of bone metastases~4. One to 3 painful lesions.~5. Targeted tumor(s) are ExAblate device accessible and are located in ribs, extremities (excluding joints), pelvis, shoulders and in the posterior aspects of the following spinal vertebra: Lumbar vertebra (L3 - L5), Sacral vertebra (S1 - S5)~6. Patients with persistent distinguishable pain associated with up to 3 tumors of which a maximum of 2 tumors will be treated:~   o If patient has pain from additional sites that are not planned for treatment, the pain from the additional sites must be evaluated as being less intense by at least 2 points on the NRS compared to the site(s) to be treated.~7. Patient with NRS (0-10 scale) pain score ≥ 4 at the targeted tumors (i.e: both tumors targeted for treatment must have NRS ≥ 4) irrespective of medication~8. Targeted tumors (most painful) size up to 8 cm in diameter~9. Patient whose targeted (most painful) tumors are on bone and bone-lesion interface is deeper than 1cm from the skin.~10. Targeted (most painful) tumors clearly visible by non-contrast MRI, and ExAblate MRgFUS device accessible~11. Able to communicate sensations during the ExAblate MRgFUS treatment~12. At least 2 weeks since chemotherapy~13. No radiation therapy to targeted (most painful) tumors in the past two weeks~Exclusion Criteria:~1. Patients who either~   * Need surgical stabilization of the affected weight bearing bony structure (\>7 fracture risk score, see Section 6.9) OR~  * Targeted tumor is at an impending fracture site of the weigh bearing bone (\>7 on fracture risk score, see Section 6.9).~   OR~   o Patients with surgical stabilization of tumor site with metallic hardware~2. More than 3 painful lesions or more than 2 requiring immediate localized treatment~3. The targeted tumor(s) is (are) less than 2 points more painful compared to other non-targeted painful lesions on the site specific NRS.~4. Targeted tumor is in the skull~5. Patients on dialysis~6. Patients with life expectancy \< 6-Months~7. Patients with an acute medical condition (e.g., pneumonia, sepsis) that is expected to hinder them from completing this study.~8. Patients with unstable cardiac status including:~   * Unstable angina pectoris on medication~  * Patients with documented myocardial infarction within six months of protocol entry~  * Congestive heart failure requiring medication (other than diuretic)~  * Patients on anti-arrhythmic drugs~9. Severe hypertension (diastolic BP \> 100 on medication)~10. Patients with standard contraindications for MR imaging such as non-MRI compatible implanted metallic devices including cardiac pacemakers, size limitations, etc.~11. Patients with an active infection or severe hematological, neurological, or other uncontrolled disease.~12. Known intolerance or allergies to the MRI contrast agent (e.g. Gadolinium or Magnevist) including advanced kidney disease~13. KPS Score \< 60 (See Definitions below)~14. Severe cerebrovascular disease (multiple CVA or CVA within 6 months)~15. Individuals who are not able or willing to tolerate the required prolonged stationary position during treatment (can be up to 4 hrs of total table time.)~16. Target (most painful) tumor-bone interface is less then 1cm from nerve bundles, bowels or bladder.~17. Are participating or have participated in another clinical trial for the palliation of their targeted bone metastasis tumors in the last 30 days~18. Patients receiving chemotherapy or radiation (i.e., to the targeted lesion (s)) within the last two weeks~19. Patients unable to communicate with the investigator and staff.~20. Patients with persistent undistinguishable pain (pain source unidentifiable)~21. Targeted (most painful) tumors size \> 8 cm in diameter~22. Targeted (most painful) tumors:~    * NOT visible by non-contrast MRI, OR~   * NOT accessible to ExAblate device

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ExAblate 2100 Treatment (Type: EXPERIMENTAL): ExAblate 2100 ablation for the treatment of painful bone metastases.

Based on this trial design, predict the completion outcome and termination type (if applicable).